Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | SLC15A2 | Q16348 | 4/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343313 | 1.00 | HSD17B10 (0.50) | HSD17B10ALDH1A1TDP1MAPTKMT2A | |
| SCHEMBL3346941 | 0.86 | ACE (0.40) | HSD17B10ALDH1A1TDP1MAPTKMT2A | |
| SCHEMBL4657601 | 0.86 | ACE (0.40) | HSD17B10ALDH1A1TDP1MAPTKMT2A | |
| SCHEMBL3343004 | 0.83 | ACE (0.38) | HSD17B10ALDH1A1TDP1MAPTKMT2A | |
| SCHEMBL6211227 | 0.76 | PSEN1 (0.45) | ACEMME | |
| SCHEMBL3343191 | 0.76 | PSEN1 (0.45) | ACEMME | |
| SCHEMBL8342122 | 0.74 | PSEN1 (0.56) | — | |
| SCHEMBL3346831 | 0.74 | PSEN1 (0.56) | — | |
| SCHEMBL14367234 | 0.72 | TSHR (0.37) | ALDH1A1KMT2AADRA1AHTR2BTSHR | |
| SCHEMBL8342144 | 0.72 | TSHR (0.37) | ALDH1A1KMT2AADRA1AHTR2BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858776-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2010-12-28 | — | — | US | disclosed |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7294622-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| EP-1845089-A1 | Novel lactams and uses thereof | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1554250-B1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| US-20060089346-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
| EP-1554250-A1 | NOVEL LACTAMS AND USES THEREOF | AstraZeneca AB (SE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004031154-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089346-A1 | Novel lactams and uses thereof | BACE1, BACE2, APH1B | HSD17B10 512/4885ALDH1A1 2343/4885TDP1 1601/4885 |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | APP, BACE1, PSEN1 | HSD17B10 1589/4885ALDH1A1 1630/4885TDP1 1730/4885 |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | BACE1, BACE2, APP | HSD17B10 655/4885ALDH1A1 2328/4885TDP1 1707/4885 |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | NOTCH1, HES1, NOTCH2 | HSD17B10 917/4885ALDH1A1 1230/4885TDP1 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.